209 related articles for article (PubMed ID: 28243795)
1. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.
Tanaka M; Hosoya A; Mori H; Kayasuga R; Nakamura H; Ozawa H
J Bone Miner Metab; 2018 Jan; 36(1):54-63. PubMed ID: 28243795
[TBL] [Abstract][Full Text] [Related]
2. Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.
Kakimoto S; Nagakura Y; Tamura S; Watabiki T; Shibasaki K; Tanaka S; Mori M; Sasamata M; Okada M
Eur J Pharmacol; 2008 Jul; 589(1-3):98-101. PubMed ID: 18565509
[TBL] [Abstract][Full Text] [Related]
3. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
4. Antagonists to TRPV1, ASICs and P2X have a potential role to prevent the triggering of regional bone metabolic disorder and pain-like behavior in tail-suspended mice.
Hanaka M; Iba K; Dohke T; Kanaya K; Okazaki S; Yamashita T
Bone; 2018 May; 110():284-294. PubMed ID: 29452264
[TBL] [Abstract][Full Text] [Related]
5. Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.
Tanishima S; Kishimoto Y; Fukata S; Mizumura H; Hagino H; Teshima R
Mod Rheumatol; 2007; 17(3):198-205. PubMed ID: 17564774
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
7. P2X3 and P2X2/3 receptors activation induces articular hyperalgesia by an indirect sensitization of the primary afferent nociceptor in the rats' knee joint.
Teixeira JM; Parada CA; Tambeli CH
Eur J Pharmacol; 2020 Jul; 879():173054. PubMed ID: 32145326
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice.
Hansen RR; Nasser A; Falk S; Baldvinsson SB; Ohlsson PH; Bahl JM; Jarvis MF; Ding M; Heegaard AM
Eur J Pharmacol; 2012 Aug; 688(1-3):27-34. PubMed ID: 22634164
[TBL] [Abstract][Full Text] [Related]
10. P2X3 and P2X2/3 Receptors Play a Crucial Role in Articular Hyperalgesia Development Through Inflammatory Mechanisms in the Knee Joint Experimental Synovitis.
Teixeira JM; Bobinski F; Parada CA; Sluka KA; Tambeli CH
Mol Neurobiol; 2017 Oct; 54(8):6174-6186. PubMed ID: 27709491
[TBL] [Abstract][Full Text] [Related]
11. Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors.
Kowalski M; Hausmann R; Schmid J; Dopychai A; Stephan G; Tang Y; Schmalzing G; Illes P; Rubini P
Neuropharmacology; 2015 Dec; 99():115-30. PubMed ID: 26184350
[TBL] [Abstract][Full Text] [Related]
12. P2X3 and P2X2/3 receptors mediate mechanical hyperalgesia induced by bradykinin, but not by pro-inflammatory cytokines, PGE₂ or dopamine.
de Oliveira Fusaro MC; Pelegrini-da-Silva A; Araldi D; Parada CA; Tambeli CH
Eur J Pharmacol; 2010 Dec; 649(1-3):177-82. PubMed ID: 20868656
[TBL] [Abstract][Full Text] [Related]
13. [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Chatani Y
Clin Calcium; 2005 Jan; 15(1):9-14. PubMed ID: 15632466
[TBL] [Abstract][Full Text] [Related]
14. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
15. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.
Neutzsky-Wulff AV; Sørensen MG; Kocijancic D; Leeming DJ; Dziegiel MH; Karsdal MA; Henriksen K
BMC Musculoskelet Disord; 2010 Jun; 11():109. PubMed ID: 20515459
[TBL] [Abstract][Full Text] [Related]
16. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
Marucci G; Dal Ben D; Buccioni M; Martí Navia A; Spinaci A; Volpini R; Lambertucci C
Expert Opin Ther Pat; 2019 Dec; 29(12):943-963. PubMed ID: 31726893
[No Abstract] [Full Text] [Related]
17. Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies.
Shcherbatko A; Foletti D; Poulsen K; Strop P; Zhu G; Hasa-Moreno A; Melton Witt J; Loo C; Krimm S; Pios A; Yu J; Brown C; Lee JK; Stroud R; Rajpal A; Shelton D
J Biol Chem; 2016 Jun; 291(23):12254-70. PubMed ID: 27129281
[TBL] [Abstract][Full Text] [Related]
18. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Garceau D; Chauret N
Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
